FDA Greenlights Key HARMONIC Phase 2 Trial Amendments for LP-300, Citing Promising Early Data
LTRN has more than doubled off its 52-week low of $1.11 on light trading volume (0.3× avg).
Summary
Lantern Pharma received favorable FDA feedback on its HARMONIC Phase 2 trial for LP-300, allowing key protocol amendments and highlighting promising early clinical data, which de-risks the program.
Key Events · Product Development and Regulatory · LTRN
-
FDA Type C Meeting Success
The FDA raised no objections to three key protocol amendments for the HARMONIC Phase 2 clinical trial of LP-300, marking a significant de-risking milestone.
-
Trial Design De-Risked
Approved amendments include enriching enrollment for EGFR Exon 21 L858R patients, extending LP-300 dosing to 8 cycles, and transitioning to a single-arm study design, which is expected to accelerate enrollment.
-
Promising Early Clinical Data
Preliminary HARMONIC™ data (n=31) show an 8.4-month median Progression-Free Survival (mPFS) and durable responses exceeding 2 years in select L858R-mutant patients.
-
Superior Tolerability Profile
LP-300 combined with chemotherapy demonstrated markedly cleaner safety compared to a competitor (amivantamab + chemo), with significantly lower rates of serious treatment-related adverse events and infusion reactions.
Analysis · LTRN · Life Sciences
Lantern Pharma disclosed detailed positive outcomes from its FDA Type C meeting for the HARMONIC Phase 2 trial of LP-300. The FDA raised no objections to critical protocol amendments, including enriching enrollment for EGFR Exon 21 L858R patients, extending dosing, and transitioning to a single-arm design. This regulatory clarity, combined with promising preliminary data showing an 8.4-month median PFS and superior tolerability, significantly de-risks the trial and provides a clearer path towards potential registration for a key asset, which is crucial for the company given its recent 'going concern' warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.3M. The 52-week trading range was $1.11 to $5.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.